Prevalence of High-Risk Human Papillomavirus (HR-HPV) Infection among Women with Normal and Abnormal Cervical Cytology in Myanmar

被引:0
作者
Mu-Mu-Shwe [1 ]
Harano, Teruo [2 ]
Okada, Shigeru [3 ]
Aye-Aye-Win [1 ]
Khin-Saw-Aye [1 ]
Hlaing-Myat-Thu [1 ]
Mo-Mo-Win [1 ]
Khin-Khin-Oo [1 ]
Myo-Khin [1 ]
机构
[1] Minist Hlth, Dept Med Res Lower Myanmar, Yangon, Myanmar
[2] Okayama Univ Hosp, Dept Gen Med, Okayama 7008558, Japan
[3] Okayama Univ, Okayama 7000811, Japan
关键词
human papillomavirus; cervical neoplasia; genotyping; Myanmar; PARTICLE VACCINE; EFFICACY; TYPE-18; DNA;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This study aimed to determine the prevalence of normal and abnormal cervical cytology in women who attended the cervical cancer screening clinic of the Department of Medical Research in Lower Myamnar, and to determine the proportion of high-risk (HR) human papillomavirus (HPV) infection and HPV genotypes in women with normal and abnormal cervical cytology. A total of 1,771 women were screened from 2010 to 2011. Among them, 762 women (43.0%) had a normal smear, and 866 (48.9%) and 87 (4.9%) were diagnosed with inflammatory smears and atypical squamous cells of undetermined significance (ASCUS), respectively. Diagnoses of low-grade squamous intraepithelial lesion (LSIL) and high-grade squamous intraepithelial lesion (HSIL) numbered 42(2.3%) and 11(0.6%) respectively. Three cases of squamous cell carcinoma (SCC) (0.2%) were detected. Cervical swabs were collected from 96 women with abnormal cervical cytology and 20 with normal cytology. HR-HPV DNA testing was performed by polymerase chain reaction (PCR) with pU1M/pU2R primers. HR-HPV were identified in 35.5% (22/62) of inflammatory smears, 60% (6/10) of ASCUS, 86.7% (13/15) of LSIL, 50% (3/6) of HSIL, 100% (3/3) of SCC and 5% (1/20) of normal cytology. In PCR-positive cases, HPV genotyping was analyzed by the cleaved amplification polymorphism method. The most prevalent HPV genotypes were HPV-16 (60.4%) followed by HPV-31 (14.6%), HPV-18 (12.5%) and HPV-58 (12.5%). Women with abnormal cervical cytology were 10 times more likely to be HR-HPV positive than those with normal cytology (p = 0.0001). This study suggests that the implementation of a cervical cytology screening program and routine vaccination against BPV in preadolescent and adolescent groups are needed to reduce the burden of HPV-associated cervical cancer.
引用
收藏
页码:79 / 87
页数:9
相关论文
共 19 条
[1]  
[Anonymous], GLOBOCAN 2008
[2]  
Aung Soe, 1974, EPIDEMIOLOGICAL OVER
[3]  
Bosch FX, 2008, VACCINES PREVENTION, V4, P45
[4]  
Bosch FX, 2008, VACCINES PREVENTION, V4, P36
[5]  
Cobo Fernando, 2009, Open Virol J, V3, P60, DOI 10.2174/1874357900903010060
[6]   Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology:: a meta-analysis [J].
de Sanjose, Silvia ;
Diaz, Mireia ;
Castellsague, Xavier ;
Clifford, Gary ;
Bruni, Laia ;
Munoz, Nubia ;
Bosch, F. Xavier .
LANCET INFECTIOUS DISEASES, 2007, 7 (07) :453-459
[7]   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917
[8]   SIMULTANEOUS DETECTION AND TYPING OF GENITAL HUMAN PAPILLOMAVIRUS DNA USING THE POLYMERASE CHAIN-REACTION [J].
FUJINAGA, Y ;
SHIMADA, M ;
OKAZAWA, K ;
FUKUSHIMA, M ;
KATO, I ;
FUJINAGA, K .
JOURNAL OF GENERAL VIROLOGY, 1991, 72 :1039-1044
[9]   Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial [J].
Harper, DM ;
Franco, EL ;
Wheeler, CM ;
Moscicki, AB ;
Romonowski, B ;
Roteli-Martins, CM ;
Jenkins, D ;
Schuind, A ;
Clemens, SAC ;
Dubin, G .
LANCET, 2006, 367 (9518) :1247-1255
[10]   PERSISTENT GENITAL HUMAN PAPILLOMAVIRUS INFECTION AS A RISK FACTOR FOR PERSISTENT CERVICAL DYSPLASIA [J].
HO, GYF ;
BURK, RD ;
KLEIN, S ;
KADISH, AS ;
CHANG, CJ ;
PALAN, P ;
BASU, J ;
TACHEZY, R ;
LEWIS, R ;
ROMNEY, S .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (18) :1365-1371